Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTeam17 Regulatory News (TM17)

  • There is currently no data for TM17

Trading Update

29 Jan 2019 07:00

RNS Number : 3209O
Team17 Group PLC
29 January 2019
 

29 January 2019

 

Team17 Group plc

("Team17", the "Group" or the "Company")

 

Trading update

 

Team17, a global games label, creative partner and developer of independent ("indie") premium video games, provides an update for the year ended 31 December 2018.

 

The Company is pleased to report it has continued to see strong sales momentum in the second half, particularly in the sales of third party titles such as Overcooked 2. The Company will therefore report revenues ahead of expectations and adjusted EBITDA at the upper end of market expectations.

 

The Company's growing back catalogue portfolio has continued to perform well over the course of 2018, demonstrating the strength of the team's capabilities in life cycle management.

 

Furthermore, the Company is pleased to see the quality of its games and people being recognised in the media and at leading industry events throughout 2018. The Company and Portfolio received over 130 Awards and Nominations in 2018, notably at the international gaming industry's flagship awards ceremony, The Game Awards, held in Los Angeles in December, where Overcooked 2 was awarded Best Family Game. Furthermore, Yoku's Island Express collected over 70 nominations or awards in the Industry's media roundup of 'Best of 2018' Games.

 

The Company has a solid portfolio of game launches planned for 2019, including My Time at Portia, which exited Early Access on 15 January 2019 and launched on both Valve's Steam Store and the Epic Games store. The game has had an encouraging start and will be launching across additional platforms in Spring 2019. Genesis Alpha One will launch today on PlayStation 4, Xbox One and on PC, exclusively via the recently launched Epic Games store. The Escapists 2: Pocket Breakout, sequel to the Company's owned multi million unit selling Escapist franchise, will also make its debut on Android (Google Play & Amazon stores) and iOS (Apple store) on 31 January 2019.

 

The Company will report its full year results for the year ended 31 December 2018 on Tuesday, 19 March 2019.

 

Enquiries:

 

Team17 Group plc

Debbie Bestwick MBE, Chief Executive Officer

Jo Jones, Chief Financial Officer

 

via Vigo Communications

 

GCA Altium (Nominated Adviser)

Adrian Reed / Paul Lines

 

+44 (0)845 505 4343

Berenberg (Broker)

Chris Bowman / Toby Flaux / Marie-Agnes Stolberg

 

+44 (0)20 3207 7800

Vigo Communications (Financial Public Relations)

Jeremy Garcia / Fiona Henson / Charlie Neish

team17@vigocomms.com

+44 (0)20 7390 0238

 

 

 

 

About Team17

 

Founded in 1990, Team17 Group plc is a leading international premium video games label and creative partner for independent developers. The portfolio comprises over 100 games, including The Escapists, Genesis Alpha One, My Time At Portia, Overcooked, Yoku's Island Express, Yooka-Laylee, the Worms franchise and many more from developers around the world. Visit www.team17.com for more info.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBPMFTMBITBIL
Date   Source Headline
19th Sep 20237:00 amRNSHalf Year Results
12th Sep 20239:00 amRNSDirector/PDMR Shareholding
22nd Aug 20237:00 amRNSBoard Update
17th Aug 20234:46 pmRNSHolding(s) in Company
14th Aug 20239:00 amRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSNotice of Results & Trading Update
19th Jul 20237:00 amRNSDirectorate Changes
18th Jul 20232:15 pmRNSDirector/PDMR Shareholding
14th Jul 20237:00 amRNSAppointment of Joint Corporate Broker
12th Jul 20233:36 pmRNSDirector/PDMR Shareholding
22nd Jun 20232:01 pmRNSResult of AGM
16th Jun 20234:27 pmRNSHolding(s) in Company
14th Jun 20238:55 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSAppointment of Group Chief Executive Officer
26th May 20237:01 amRNSBoard Update
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
25th May 20234:42 pmRNSHolding(s) in Company
15th May 202312:50 pmRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSTeam17's astragon Acquires Independent Arts
13th Apr 20233:40 pmRNSIssue of Shares
12th Apr 20238:20 amRNSDirector/PDMR Shareholding
31st Mar 202311:15 amRNSDirector/PDMR Shareholding
28th Mar 20237:01 amRNSDirector Update
28th Mar 20237:00 amRNSUnaudited Final Results 2022
13th Mar 20234:49 pmRNSDirector/PDMR Shareholding
13th Mar 20239:05 amRNSNo Material Exposure to Silicon Valley Bank
2nd Mar 20237:00 amRNSNotice of Results & Analyst/Investor Presentations
13th Feb 20231:41 pmRNSDirector/PDMR Shareholding
31st Jan 20232:40 pmRNSHoldings in Company
19th Jan 20235:20 pmRNSHolding(s) in Company
18th Jan 20237:00 amRNSTrading Update
12th Jan 20239:04 amRNSDirector/PDMR Shareholding
10th Jan 20236:19 pmRNSHolding(s) in Company
9th Jan 20232:48 pmRNSTrading Update
13th Dec 20223:51 pmRNSDirector/PDMR Shareholding
17th Nov 20228:46 amRNSHolding(s) in Company
11th Nov 20225:13 pmRNSDirector/PDMR Shareholding
20th Oct 202212:11 pmRNSHolding(s) in Company
18th Oct 20221:42 pmRNSDirector/PDMR Shareholding
13th Sep 20224:32 pmRNSDirector/PDMR Shareholding
13th Sep 20227:00 amRNSHalf Year Results
5th Sep 20227:00 amRNSNotice of Results & Analyst/Investor presentations
12th Aug 20221:29 pmRNSDirector/PDMR Shareholding
18th Jul 20225:08 pmRNSHolding(s) in Company
15th Jul 20223:25 pmRNSHolding(s) in Company
14th Jul 20227:00 amRNSTrading Update
12th Jul 20223:56 pmRNSDirector/PDMR Shareholding
30th Jun 20223:58 pmRNSGrant of Options to Directors / PDMRs
29th Jun 20224:39 pmRNSResult of AGM
15th Jun 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.